Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia

Lumenta, David B.; Plesnila, Nikolaus; Kläsner, Benjamin; Baethmann, A.; Pruneau, Didier; Schmid-Elsaesser, Robert; Zausinger, Stefan

doi:10.1016/j.brainres.2005.11.043

Cited by 19 publications

(8 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several model-specific complications have also been reported: non-adequate or insufficient occlusion (Laing et al, 1993), intraluminal thrombus formation (Koizumi et al, 1986;Muller et al, 1994;Rabb, 1996), subarachnoid hemorrhage (Longa et al, 1989;Laing et al, 1993), and hyperthermia (Memezawa et al, 1995). Despite these complications, the filament model is frequently used and suitable for drug related studies (Villa et al, 2007;Lyden et al, 2000;Nagel et al, 2007;Qiu et al, 2006;Zhao et al, 2006;Lumenta et al, 2006). A current ongoing study in our lab involves the administration of erythropoietin in aged rats in conjunction with the filament MCAO model.…”

Section: Discussionmentioning

confidence: 99%

Endothelin-1 induced MCAO: Dose dependency of cerebral blood flow

Nikolova

Moyanova

Hughes

et al. 2009

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Endothelin-1 induced MCAO: Dose dependency of cerebral blood flow

Nikolova

Moyanova

Hughes

et al. 2009

Journal of Neuroscience Methods

View full text Add to dashboard Cite

“…A PE-50 cathether was inserted into the right femoral artery to monitor arterial blood pressure (ABP), heart rate (HR), blood gases, and pH. A burr hole was drilled 5 mm right lateral and 1 mm posterior to bregma and the laser Doppler flowmeter probe was placed above the dura to continuously record regional cerebral blood flow (rCBF) starting from prior to the onset of ischemia until early after reperfusion (Blood Flow Meter, ADInstruments, Colorado Springs, CO) [13–15]. Transient right MCAO was induced by an intraarterial filament (diameter: 0.39 ± 0.02 mm; Doccol Corporation, Redlands, CA) and lasted for 2 hours [1,16].…”

Section: Methodsmentioning

confidence: 99%

Electrical Stimulation of the Vagus Nerve Dermatome in the External Ear is Protective in Rat Cerebral Ischemia

Napadow

2015

Brain Stimulation

View full text Add to dashboard Cite

Background Although cervical vagus nerve stimulation is effective for reducing infarct volume in rats, it is not feasible for acute human stroke as it requires surgical incision of the neck. We hypothesized that stimulation of the dermatome in the external ear innervated by the vagus nerve (auricular vagus nerve stimulation; aVNS) reduces infarct volume after transient focal ischemia in rats. Methods Animals were randomized to active aVNS or sham stimulation. For aVNS, electrical stimulation of the left cavum concha (1 hour duration) using percutaneous needles was initiated 30 min after induction of ischemia. Behavioral and tissue outcome were measured 24 hours after induction of ischemia. In a separate experimental dataset, c-Fos immunohistochemistry was performed to identify the brain regions activated after the stimulation. Results Stimulation of the left cavum concha resulted in bilateral c-Fos staining in the nuclei tractus solitarii and the loci coerulei in all animals. There was no c-Fos staining in any part of the brainstem in sham control animals. The mean infarct volume (SD) as calculated by indirect method was 44.20 ± 7.58% in controls and 31.65 ± 9.67% in treated animals (p<0.0001). The effect of aVNS on tissue outcome was associated with better neurological scores at 24 hours after ischemia (p<0.0001). Conclusions Electric stimulation of the vagus nerve dermatome in the external ear activates brainstem afferent vagal nuclei and reduces infarct volume in rats. This finding has potential to facilitate the development of treatments that leverage the brain’s endogenous neuroprotective pathways at the setting of acute ischemic stroke.

show abstract

“…epidermal growth factor [58], vascular endothelial growth factor [104], basic fibroblast growth factor [105], insulin-like growth factors (IGF-I and -II) [106]), biotin-binding proteins (avidin, streptavidin, or neutravidin) [107], insulin [59,69], albumin [108-110], leptin [111,112], lactoferrin [103,113], iron binding protein p97 (melanotransferrin) [114], transferrin [68,115] and Angiopep-2 [84]. Some agents play a pivotal role in enhancing the permeability of nanoprobes through BBB [116-132]. A list of agents/condition and their effects on BBB are summarized in Table 1.…”

Section: Np Mediated Brain Delivery Systemsmentioning

confidence: 99%

Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging

et al. 2010

View full text Add to dashboard Cite

Nanotechnology has brought a variety of new possibilities into biological discovery and clinical practice. In particular, nano-scaled carriers have revolutionalized drug delivery, allowing for therapeutic agents to be selectively targeted on an organ, tissue and cell specific level, also minimizing exposure of healthy tissue to drugs. In this review we discuss and analyze three issues, which are considered to be at the core of nano-scaled drug delivery systems, namely functionalization of nanocarriers, delivery to target organs and in vivo imaging. The latest developments on highly specific conjugation strategies that are used to attach biomolecules to the surface of nanoparticles (NP) are first reviewed. Besides drug carrying capabilities, the functionalization of nanocarriers also facilitate their transport to primary target organs. We highlight the leading advantage of nanocarriers, i.e. their ability to cross the blood-brain barrier (BBB), a tightly packed layer of endothelial cells surrounding the brain that prevents high-molecular weight molecules from entering the brain. The BBB has several transport molecules such as growth factors, insulin and transferrin that can potentially increase the efficiency and kinetics of brain-targeting nanocarriers. Potential treatments for common neurological disorders, such as stroke, tumours and Alzheimer's, are therefore a much sought-after application of nanomedicine. Likewise any other drug delivery system, a number of parameters need to be registered once functionalized NPs are administered, for instance their efficiency in organ-selective targeting, bioaccumulation and excretion. Finally, direct in vivo imaging of nanomaterials is an exciting recent field that can provide real-time tracking of those nanocarriers. We review a range of systems suitable for in vivo imaging and monitoring of drug delivery, with an emphasis on most recently introduced molecular imaging modalities based on optical and hybrid contrast, such as fluorescent protein tomography and multispectral optoacoustic tomography. Overall, great potential is foreseen for nanocarriers in medical diagnostics, therapeutics and molecular targeting. A proposed roadmap for ongoing and future research directions is therefore discussed in detail with emphasis on the development of novel approaches for functionalization, targeting and imaging of nano-based drug delivery systems, a cutting-edge technology poised to change the ways medicine is administered.

show abstract

Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia

Cited by 19 publications

References 58 publications

Endothelin-1 induced MCAO: Dose dependency of cerebral blood flow

Endothelin-1 induced MCAO: Dose dependency of cerebral blood flow

Electrical Stimulation of the Vagus Nerve Dermatome in the External Ear is Protective in Rat Cerebral Ischemia

Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging

Contact Info

Product

Resources

About